​

Intra-Cellular Therapies Ownership | Who Owns Intra-Cellular Therapies?

OverviewForecastRevenueFinancialsChartTranscripts

Intra-Cellular Therapies Ownership Summary

Intra-Cellular Therapies is owned by 14.68% institutional investors, 2.48% insiders, and 82.83% retail investors. Fmr is the largest institutional shareholder, holding 10.47% of ITCI shares. Fidelity Growth Compy Commingled Pl O is the top mutual fund, with 3.69% of its assets in Intra-Cellular Therapies shares.

ITCI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockIntra-Cellular Therapies14.68%2.48%82.83%
SectorHealthcare Stocks 279.19%10.62%-189.81%
IndustrySpecialty & Generic Drug Manufacturers Stocks2774.71%11.85%-2686.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr11.08M10.47%$925.10M
Vanguard group9.72M9.19%$811.93M
Blackrock6.32M6.53%$432.97M
Blackrock funding, inc. /de6.11M5.78%$510.53M
Pentwater capital management lp5.19M5.03%$684.66M
Jpmorgan chase5.13M4.85%$428.13M
Norges bank3.21M3.04%$268.35M
Invesco3.08M2.91%$257.01M
Deep track capital, lp2.00M1.94%$263.84M
State street1.80M1.86%$123.44M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Twin securities440.69K30.04%$58.14M
Taconic capital advisors lp443.70K14.07%$58.53M
One68 global capital197.33K12.78%$26.03M
Vazirani asset management25.00K12.14%$3.30M
Kryger capital750.57K11.61%$99.02M
Deep track capital, lp2.00M8.54%$263.84M
Artia global partners lp219.72K7.34%$28.99M
Melqart asset management (uk)400.69K6.89%$52.86M
First trust capital management719.55K6.86%$94.92M
P schoenfeld asset management lp176.50K6.53%$23.28M

Top Buyers

HolderShares% AssetsChange
Pentwater capital management lp5.19M5.75%5.19M
Norges bank3.21M0.04%3.21M
Raymond james financial915.36K0.03%915.36K
Kryger capital750.57K11.61%750.57K
First trust capital management719.55K6.86%719.55K

Top Sellers

HolderShares% AssetsChange
Wasatch advisors lp---3.25M
Bellevue group---2.44M
Avoro capital advisors625.00K1.29%-2.42M
Blackrock6.32M0.01%-1.76M
Clearbridge investments---1.69M

New Positions

HolderShares% AssetsChangeValue
Pentwater capital management lp5.19M5.75%5.19M$684.66M
Norges bank3.21M0.04%3.21M$268.35M
Raymond james financial915.36K0.03%915.36K$76.45M
Kryger capital750.57K11.61%750.57K$99.02M
First trust capital management719.55K6.86%719.55K$94.92M

Sold Out

HolderChange
Financial gravity asset management-1.00
Sanctuary wealth management-1.00
Continuum advisory-6.00
Financial synergies wealth advisors-6.00
Brown brothers harriman-7.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202534-91.41%15,144,357-84.34%140.18%26-87.32%3-97.79%
Dec 31, 2024239-34.16%67,046,839-28.51%630.81%120-32.20%85-32.54%
Sep 30, 2024361-5.99%93,782,613-2.67%881.03%176-18.14%126-0.79%
Jun 30, 20243783.00%96,330,66610.68%991.21%21019.32%127-
Mar 31, 20243675.16%87,032,607-2.57%901.05%176-3.83%12711.40%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl O3.90M3.69%-95.00K
Fidelity Growth Compy Commingled Pl S3.87M3.64%38.13K
Vanguard US Total Market Shares ETF3.21M3.02%2.64K
Vanguard Total Stock Mkt Idx Inv3.19M3.00%12.02K
Fidelity Growth Company Fund2.66M2.51%-86.64K
Vanguard Small Cap Index2.52M2.37%-50.90K
BB Biotech AG Ord2.42M2.28%-45.00K
BlackRock Event Driven Equity Instl1.83M1.72%-
Vanguard Institutional Extnd Mkt Idx Tr1.52M1.43%21.95K
Vanguard Small Cap Growth Index Inv1.41M1.33%-31.14K

Recent Insider Transactions

DateNameRoleActivityValue
Dec 05, 2024Mates Sharon Chairman and CEOSell$129.91K
Dec 04, 2024Mates Sharon Chairman and CEOSell$2.01M
Dec 04, 2024Mates Sharon Chairman and CEOSell$2.37M
Dec 05, 2024Mates Sharon Chairman and CEOSell$4.22M
Nov 12, 2024Halstead Michael PresidentSell$149.79K

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1--
2024 Q4-9
2024 Q3-17
2024 Q2-3

ITCI Ownership FAQ

Who Owns Intra-Cellular Therapies?

Intra-Cellular Therapies shareholders are primarily institutional investors at 14.68%, followed by 2.48% insiders and 82.84% retail investors. The average institutional ownership in Intra-Cellular Therapies's industry, Specialty & Generic Drug Manufacturers Stocks, is 2774.71%, which Intra-Cellular Therapies falls below.

Who owns the most shares of Intra-Cellular Therapies?

Intra-Cellular Therapies’s largest shareholders are Fmr (11.08M shares, 10.47%), Vanguard group (9.72M shares, 9.19%), and Blackrock (6.32M shares, 6.53%). Together, they hold 26.19% of Intra-Cellular Therapies’s total shares outstanding.

Does Blackrock own Intra-Cellular Therapies?

Yes, BlackRock owns 6.53% of Intra-Cellular Therapies, totaling 6.32M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 432.97M$. In the last quarter, BlackRock decreased its holdings by -1.756M shares, a -21.74% change.

Who is Intra-Cellular Therapies’s biggest shareholder by percentage of total assets invested?

Twin securities is Intra-Cellular Therapies’s biggest shareholder by percentage of total assets invested, with 30.04% of its assets in 440.69K Intra-Cellular Therapies shares, valued at 58.14M$.

Who is the top mutual fund holder of Intra-Cellular Therapies shares?

Fidelity Growth Compy Commingled Pl O is the top mutual fund holder of Intra-Cellular Therapies shares, with 3.69% of its total shares outstanding invested in 3.9M Intra-Cellular Therapies shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools